Tocilizumab
Add to cart
Tocilizumab anti-IL-6R) is a humanized monoclonal antibody that binds to the interleukin-6 receptor
[accordions]
[accordion title= “Cell Research“]
[accordion title= “Cell Research“]
Objective: To validate that IL-6 signaling is essential for TAM (tumor-associated macrophages)-enhanced CSC (cancer stem cells) function. Concentrations: 5 μg/ml. Incubation Time: 72 h. Method: For co-culture experiments, 12-well Transwell chambers were used with 2×105 HepG2 or Hep3B cells seeded in the lower chamber one day before co-culture and either 5×105 or 1×106 TAMs added in the upper chamber. Tocilizumab or human IgG antibody were added in indicated experiments to selected wells. After 24 to 72 hours, HCC cells and CD14+ TAM cells were collected separately for analysis. Cells:HepG2 cell lines, TAMs isolated from HCCs (hepatocellular carcinoma)
[/accordion]
[accordions]
[accordion title= “References and Literature“]
[accordion title= “References and Literature“]
1. Garbers C, et al. Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor. J Biol Chem. 2011 Dec 16;286(50):42959-702. Kim NH, et al. Anti-proliferative action of IL-6R-targeted antibody tocilizumab for non-small cell lung cancer cells. Oncol Lett. 2015 May;9(5):2283-2288.3. Shinriki S, et al. Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma. Clin Cancer Res. 2009 Sep 1;15(17):5426-34.
[/accordion]
[accordions]
[accordion title= “Chemical Properties“]
[accordion title= “Chemical Properties“]
| Molecular Weight | 148 kDa |
| CAS No. | 375823-41-9 |
[/accordion]
